Dr Schneider on Diagnostic Testing Turnaround Times in Lung Cancer

Dr Rodriguez on Treating Patients With Lung Cancer Harboring Multiple Actionable Mutations

Dr Olazagasti on the Use of Biomarker Testing in Lung Cancer

Dr Kim on NSCLC Treatment Selection Based on Biomarker Testing Results

Dr Pellini on Comprehensive Genomic Profiling and Repeat Biomarker Testing in NSCLC

Key Elements of an NGS Testing Report

Interpreting the Results of an NGS Testing Report

How is Biomarker Testing Performed and Utilized?

Addressing Concerns Regarding Biomarker Testing

Tissue and Plasma-Based Mechanisms of Resistance to First-Line Osimertinib in EGFR-Mutant NSCLC: A Multi-Institutional Cohort

Predictive Biomarkers for Treatment With Amivantamab Plus Lazertinib Among EGFR-Mutated NSCLC in the Post-Osimertinib Setting: Analysis of Tissue IHC and ctDNA NGS

Real-World Testing and Treatment Patterns Among Patients With Stage IV NSCLC: A Retrospective Observational Study

Contemporary Biomarker Testing Rates in Both Early and Advanced NSCLC: Results From the MYLUNG Pragmatic Study

What is NGS Testing?

What is DNA and RNA Testing in Biomarker Testing?

Why Are You Choosing a Certain Testing Platform in Biomarker Testing?

How Do You Explain Adjuvant Therapy in NSCLC?

When Should Patients With NSCLC be Referred to Thoracic Surgeons in Specialized Centers of Care?

What are the Benefits and Side Effects of TKIs?

What is a Biomarker in the Context of Tumors?

What is a Gene Mutation and a Gene Fusion?

What is a Chromosomal Rearrangement?

How Do You Explain Neoadjuvant Therapy in NSCLC?

What are Challenges Around Access to Testing?

What are the Benefits and Side Effects of Immunotherapy?